Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Status:
NOT_YET_RECRUITING
Trial end date:
2031-05-01
Target enrollment:
Participant gender:
Summary
This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies.
Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a follow-up call one month after your final clinic visit.
Phase:
PHASE2
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
American Lung Association American Lung Association Asthma Clinical Research Centers Genentech, Inc. National Institute of Allergy and Infectious Diseases (NIAID)